Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.195 CAD | +2.63% | +11.43% | -7.14% |
Apr. 08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
Mar. 28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.51M |
---|---|---|---|---|---|
Net income 2022 | -6M -8.21M | Net income 2023 | -6M -8.21M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.07M | Net cash position 2023 | 808K 1.11M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
1 day | +2.63% | ||
1 week | +11.43% | ||
Current month | +8.33% | ||
1 month | -7.14% | ||
3 months | -9.30% | ||
6 months | -2.50% | ||
Current year | -7.14% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Director of Finance/CFO | 59 | Feb. 13 | |
Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22-04-17 | |
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Malgorzata Laube
BRD | Director/Board Member | - | 22-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 0.195 | +2.63% | 2,000 |
24-04-23 | 0.19 | 0.00% | 20,272 |
24-04-22 | 0.19 | +8.57% | 2,000 |
24-04-17 | 0.175 | -12.50% | 5,056 |
Delayed Quote Toronto S.E., April 24, 2024 at 09:30 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.14% | 32.61M | |
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- HBP Stock